NCT05570279 (PLAN-A) is a clinical trial in Anal Cancer, sponsored by Aarhus University Hospital.

Who is sponsoring NCT05570279?

NCT05570279 is sponsored by Aarhus University Hospital.

What condition does NCT05570279 study?

NCT05570279 studies Anal Cancer.

Is NCT05570279 still recruiting?

NCT05570279 is currently active, enrolled. Last updated 14 August 2024.

Last reviewed 2024-08-14 · How we verify

NCT05570279: PLAN-A

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

PLAN-A Data- Bio- and Plan- Bank Collection for SCCA in Denmark

Active, enrolled Last updated 14 August 2024

What this trial tests

trial in Anal Cancer in 314 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

1 April 2016

Primary endpoint
1 April 2025

1 April 2026

Quick facts

Lead sponsor	Aarhus University Hospital
Status	Active, enrolled
Study type	OBSERVATIONAL
Enrollment	314
Start date	1 April 2016
Primary completion	1 April 2025
Estimated completion	1 April 2026
Sites	3 locations across Denmark

Conditions studied

Anal Cancer — all drugs for Anal Cancer →

Sponsor

Aarhus University Hospital

Who can join

18 and older, any sex, with Anal Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study is a prospective registration of treatment related-, toxicity-, Quality of life- and outcome data from patients treated in Denmark with radiotherapy for squamous cell carcinoma of the anus (SCCA), as a cooperation within the Danish Anal Cancer Group (DACG). Substudy one: A prospective biobank is collected with the purpose to identify predictive and prognostic markers for outcome. Substudy two: MRI scans are performed to investigate the rate of pelvic insufficience fractures at one year post chemoradiotherapy.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

ROAR-A: re-optimization based Online Adaptive Radiotherapy of anal cancer, a prospective phase II trial protocol.
Storm KS, Åström LM, Sibolt P, Behrens CP, et al · · 2024 · cited 2× · PMID 38528456 · DOI 10.1186/s12885-024-12111-1
The prognostic value of cell-free DNA dynamics during chemoradiotherapy in squamous cell carcinomas of the anus.
Jakobsen AV, Kronborg C, Ramlov A, Hvid CA, et al · · 2026 · cited 1× · PMID 40985905 · DOI 10.1002/ijc.70156
Vaginal and sexual health after radiotherapy for anal cancer: A Danish prospective cohort study.
Steffensen JH, Serup-Hansen E, Jakobsen AV, Kronborg CJS, et al · · 2026 · PMID 41903610 · DOI 10.1016/j.radonc.2026.111496
Predictors of acute and late diarrhea in the treatment of anal cancer with concurrent chemoradiotherapy.
Storm KS, Spindler KG, Persson GF, Behrens C, et al · · 2025 · PMID 40955104 · DOI 10.2340/1651-226x.2025.43975

Verify or expand the search:

Other recruiting trials for Anal Cancer

Currently open trials in the same condition.

NCT07192055 — Self-sampling to Optimize Anal Lesion Outcomes · NA · recruiting
NCT07296237 — Beyond Survival: Addressing Gynecological and Sexual Health in Women After Radiotherapy for Anal Cancer · recruiting
NCT07124000 — DESTINY-PANTUMOUR04 · recruiting
NCT05639972 — E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers · Phase 1, PHASE2 · recruiting
NCT06670495 — HPV Genotype Attribution and Disease Burden of Anal Cancer in China · recruiting

Other Aarhus University Hospital trials

Trials by the same sponsor.

NCT07432802 — Sublobar Wedge Resection or Stereotactic Radiotherapy Treatment of High-risk Patients With Early-stage Lung Cancer · NA · not yet recruiting
NCT07499336 — UNDERSTANDING THE T-CELL AND B-CELL RECEPTOR REPERTOIRE IN CHILDREN AND YOUNG ADULTS WITH ANTI-DRUG ANTIBODIES AGAINST P · not yet recruiting
NCT07454486 — TRACE-BTC. Relation of Biomarkers and Patients Reported Quality of Life to Outcomes in Patients With Biliary Tract Cance · not yet recruiting
NCT07284069 — Senicapoc and Perampanel for Newly Diagnosed Glioblastoma · EARLY_PHASE1 · recruiting
NCT07426250 — Clinical Utility of ctDNA in the Treatment of Oligometastatic Disease · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05570279 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Aarhus University Hospital
Last refreshed: 14 August 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05570279.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing